LAG-3 in Cancer Immunotherapy: A Comprehensive Review

LAG-3 (CD223) is a cell surface protein that is present on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. It plays a crucial but not yet fully understood role in the activity of these immune cells. LAG-3 primarily interacts with Class II MHC molecules, and this interaction i...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Advanced Research in Science, Communication and Technology pp. 21 - 28
Main Authors Dr. Prafulla R Tathe, Kishor B. Charhate, Dr. Purushottam R. Laddha, Dr. Gopal R. Sitaphale
Format Journal Article
LanguageEnglish
Published 05.09.2024
Online AccessGet full text

Cover

More Information
Summary:LAG-3 (CD223) is a cell surface protein that is present on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. It plays a crucial but not yet fully understood role in the activity of these immune cells. LAG-3 primarily interacts with Class II MHC molecules, and this interaction is believed to influence dendritic cell function. Recent research has highlighted LAG-3's involvement in the exhaustion of CD8+ T cells, a state that impairs their effectiveness against tumors. Therapeutic approaches that block the interaction between LAG-3 and Class II MHC, such as the use of a LAG-3 Ig fusion protein, are currently being explored in clinical trials for cancer treatment. This review will provide an overview of the structural and functional aspects of LAG-3, followed by a discussion of preclinical and clinical findings relevant to its role in cancer immunotherapy
ISSN:2581-9429
2581-9429
DOI:10.48175/IJARSCT-19504